239000002157 polynucleotide Substances 0.000 claims description 242.229920000023 polynucleotide Polymers 0.000 claims description 242.201000010099 disease Diseases 0.000 claims abstract description 25.108091007172 antigens Proteins 0.000 claims abstract description 316.102000038129 antigens Human genes 0.000 claims abstract description 316.239000000427 antigen Substances 0.000 claims abstract description 318.230000027455 binding Effects 0.000 claims abstract description 330.108010027440 Immunoconjugates Proteins 0.000 title claims abstract description 820.

102000018748 Immunoconjugates Human genes 0.000 title claims abstract description 820.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority to US23458409P priority Critical Priority to US61/234,584 priority Priority to EP10162410.4 priority Priority to EP10162410 priority Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag Priority claimed from BR112012003739-0A external-priority patent/BR112012003739A2/en Publication of WO2011020783A2 publication Critical patent/WO2011020783A2/en Publication of WO2011020783A3 publication Critical patent/WO2011020783A3/en Links ( en Inventor Ralf Hosse Ekkehard Moessner Michela Silacci-Melkko Pablo Umana Original Assignee Roche Glycart Ag Priority date (The priority date is an assumption and is not a legal conclusion. Google Patents WO2011020783A2 - Targeted immunoconjugates WO2011020783A2 - Targeted immunoconjugates

Aq4 mage drops